193205-28-6

Upstream product

• 6940-76-7 1-iodo-3-chloro-propane 
• 610-81-1 4-hydroxy-2-nitroaniline 
• 584-08-7 potassium carbonate 
• 57925-57-2 N-[4-(3-chloropropoxy)-2-nitrophenyl]acetamide 

Downstream Products

• 958264-62-5 C₁₉H₂₄N₄O₃ 
• 958264-63-6 C₂₀H₂₆N₄O₄ 
• 958264-64-7 C₂₃H₂₆N₄O₃ 
• 958264-65-8 C₂₀H₂₃F₃N₄O₃ 

Relevant academic research and scientific papers

Two new phenylpiperazines with atypical antipsychotic potential

Two new series of substituted arylpiperazines with heterocyclic 3-propoxy-benzimidazole or 3-propoxy-benzimidazole-2-thione groups were synthesized and their in vitro binding affinities for the D2, 5-HT1A, 5-HT2A, and αsu

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.